Centrexion Therapeutics Corporation
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
6
Ending by 2030
Aug 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 30, 2026The maintenance fee for Process and Intermediates for the Production of CCR2 Antagonists (US 9,067,951) comes due Dec 30, 2026. Unpaid by Jun 30, 2027, it lapses early.
- 2 fees due Feb 15 to 22, 2027 · next Feb 15
- 1 fee due May 21, 2027The maintenance fee for Capsaicinoid Prodrug Compounds and Their Use in Treating Medical Conditions (US 11,820,727) comes due May 21, 2027. Unpaid by Nov 22, 2027, it lapses early.
- 1 fee due Jun 3, 2027The maintenance fee for Stable Aqueous Capsaicin Injectable Formulations and Medical Uses Thereof (US 10,493,047) comes due Jun 3, 2027. Unpaid by Dec 3, 2027, it lapses early.
- 1 fee due Jul 16, 2027The maintenance fee for Compositions and Methods for Intrathecal Administration of Mcoppb for Pain Relief (US 11,872,219) comes due Jul 16, 2027. Unpaid by Jan 18, 2028, it lapses early.
- 2 fees due Aug 25, 2027
Recent changes
- 1 term has ended since Aug 23, 2026
- Sep 16 US 8,835,440 Cyclic PYRIMIDIN-4-Carboxamides as CCR2 Receptor Antagonists for Treatment of Inflammation, Asthma and Copd · lapsed on the fee record
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,119,694 | High Concentration Local Anesthetic Formulations In force · Medium confidence | In force | Medium confidence | |
| US 11,517,546 | High Concentration Local Anesthetic Formulations In force · Medium confidence | In force | Medium confidence | |
| US 9,067,951 | Process and Intermediates for the Production of CCR2 Antagonists In force · High confidence | In force | High confidence | |
| US 10,196,402 | New CCR2 Receptor Antagonists and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,046,706 | CCR2 Receptor Antagonists and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,731,981 | CCR2 Receptor Antagonists and Uses Thereof In force · High confidence | In force | High confidence | |
| US 9,670,222 | New CCR2 Receptor Antagonists and Uses Thereof In force · High confidence | In force | High confidence | |
| US 9,371,282 | New Somatostatin receptor subtype 4 (SSTR4) agonists In force · High confidence | In force | High confidence | |
| US 9,789,082 | New Somatostatin Receptor Subtype 4 (SSTR4) Agonists In force · High confidence | In force | High confidence | |
| US 10,166,214 | Somatostatin Receptor Subtype 4 (SSTR4) Agonists In force · High confidence | In force | High confidence |
Also on record, not counted in the 35: 8 lapsed for an unpaid fee · 1 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
6 pending · 6 abandoned · 4 no status recorded